Can a new injection help shed excess weight?

NCT ID NCT07767175

NEW Not yet recruiting Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Aug 17, 2026 · Last updated Aug 17, 2026

Summary

This early-stage trial is investigating whether an experimental drug called NNC0721-8060 is safe and how it works in adults with overweight or obesity. Participants will receive either the new drug, a placebo, or an existing weight-management medication (semaglutide) via injection. The study will monitor side effects and measure changes in body weight to see if the drug shows promise for weight management.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NNC0721-8060, an experimental drug given as an injection, compared with semaglutide and placebo
What this could lead to: If successful, this could lead to a new treatment option for weight management in people with overweight or obesity.
What could go wrong: This is an early-phase trial focused on safety and how the drug works, so it is not yet known if it will be effective or safe for long-term use. Side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY OVERWEIGHT

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

ICON

San Antonio, Texas, 78209, United States
ICON Early Phase Services, LLC

Lenexa, Kansas, 66219, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.